FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
dwmoskowitz@genomed.com
Tel. 314.983.9938
ST. LOUIS—June 18, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it is launching a world-wide campaign to eradicate kidney dialysis by 2014.
GenoMed published in 2002 how to reverse early-stage kidney failure in patients with type 2 diabetes or high blood pressure. Globally, these two diseases cause over 90% of kidney failure that requires dialysis with the kidney machine.
David W. Moskowitz, MD FACP, GenoMed’s CEO and Chief Medical Officer, said “Education is all that’s needed to eliminate 90% of new cases of kidney failure. We have to get to patients with diabetes or high blood pressure before their serum creatinine is 2. Most patients have no idea what their serum creatinine is. But it’s more important than their cholesterol. You’ve already lost half your kidney function when your serum creatinine is 2 [mg/dl]. In four years, unless you go on our program, you’ll be on dialysis.”
Dr. Moskowitz continued, “There are currently 300,000 people on dialysis in the US. Every year, 100,000 more Americans go on dialysis. If we could take care of the 80 million Americans with diabetes or high blood pressure, we could cut this number down to 10,000 new patients a year. With 25,000 kidney transplants a year in the US, there’d be more than enough kidneys available for every one of these patients to get a kidney transplant. That’s why our slogan is ‘Dialysis-free in Five.'”
Dr. Moskowitz ended by saying, “We call on everybody seeing patients, especially primary care providers and pharmacists, to help us reach our goal of ‘Free in Five.’ All it takes is a blood pressure cuff and our recipe. The drugs we use are generic and every drugstore carries them. The only thing lacking is awareness. Fortunately, in the Internet Age, everybody’s message can finally be heard.”
About GenoMed
GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™, GenoMed aims to arrest diabetes, hypertension, and emphysema everywhere on earth. Please contact Dr. Moskowitz if you have one of these diseases.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.